Characteristics and risk factors for cardiovascular disease in patients treated with allogeneic HSCT with and without an arterial vascular event
| Characteristics numbers . | No arterial event n =247 . | With arterial event n =18 . | P . |
|---|---|---|---|
| Male gender, no. (%) | 132 (53%) | 13 (72%) | .122 |
| Median age at transplantation, y (range) | 26 (2-60) | 39 (19-59) | .002 |
| Median age at last follow-up, y (range) | 38 (6-66) | 48 (29-62) | <.001 |
| Median time of follow-up, y (range) | 9 (2-24) | 9 (2-21) | .115 |
| Alive at last follow-up, no. (%) | 196 (79%) | 12 (67%) | .20 |
| Disease and transplant-related factors, no. (%) | |||
| Acute myeloid leukemia | 71 (29%) | 8 (45%) | — |
| Chronic myeloid leukemia | 69 (28%) | 6 (33%) | .007 |
| Myelodysplastic or myeloproliferative syndrome | 13 (5%) | 4 (22%) | — |
| Acute lymphoid leukemia | 51 (21%) | 0 | — |
| Mature lymphoid neoplasia | 19 (7%) | 0 | — |
| Aplastic anemia | 24 (10%) | 0 | — |
| Total body irradiation for conditioning, no. (%) | |||
| No | 35 (14%) | 1 (6%) | .30 |
| Yes | 212 (86%) | 17 (94%) | — |
| Type of total body irradiation (n =229), no. (%) | |||
| Single fraction (10 Gy) | 48 (23%) | 5 (29%) | .52 |
| Fractionated TBI (6 × 2Gy) | 164 (77%) | 12 (71%) | — |
| Acute graft-versus-host disease (n =263), no. (%) | |||
| Grade 0 | 54 (22%) | 5 (28%) | .53 |
| Grade 1 | 72 (29%) | 5 (28%) | — |
| Grade 2 or higher | 119 (49%) | 8 (44%) | — |
| Chronic graft-versus-host disease (n=262), no. (%) | |||
| None | 111 (46%) | 11 (61%) | .57 |
| Moderate | 93 (38%) | 6 (33%) | — |
| Severe extended | 40 (16%) | 1 (6%) | — |
| Any graft-versus-host disease (n =262), no. (%) | |||
| Never | 33 (13%) | 4 (22%) | .30 |
| Yes | 211 (94%) | 14 (78%) | — |
| Characteristics numbers . | No arterial event n =247 . | With arterial event n =18 . | P . |
|---|---|---|---|
| Male gender, no. (%) | 132 (53%) | 13 (72%) | .122 |
| Median age at transplantation, y (range) | 26 (2-60) | 39 (19-59) | .002 |
| Median age at last follow-up, y (range) | 38 (6-66) | 48 (29-62) | <.001 |
| Median time of follow-up, y (range) | 9 (2-24) | 9 (2-21) | .115 |
| Alive at last follow-up, no. (%) | 196 (79%) | 12 (67%) | .20 |
| Disease and transplant-related factors, no. (%) | |||
| Acute myeloid leukemia | 71 (29%) | 8 (45%) | — |
| Chronic myeloid leukemia | 69 (28%) | 6 (33%) | .007 |
| Myelodysplastic or myeloproliferative syndrome | 13 (5%) | 4 (22%) | — |
| Acute lymphoid leukemia | 51 (21%) | 0 | — |
| Mature lymphoid neoplasia | 19 (7%) | 0 | — |
| Aplastic anemia | 24 (10%) | 0 | — |
| Total body irradiation for conditioning, no. (%) | |||
| No | 35 (14%) | 1 (6%) | .30 |
| Yes | 212 (86%) | 17 (94%) | — |
| Type of total body irradiation (n =229), no. (%) | |||
| Single fraction (10 Gy) | 48 (23%) | 5 (29%) | .52 |
| Fractionated TBI (6 × 2Gy) | 164 (77%) | 12 (71%) | — |
| Acute graft-versus-host disease (n =263), no. (%) | |||
| Grade 0 | 54 (22%) | 5 (28%) | .53 |
| Grade 1 | 72 (29%) | 5 (28%) | — |
| Grade 2 or higher | 119 (49%) | 8 (44%) | — |
| Chronic graft-versus-host disease (n=262), no. (%) | |||
| None | 111 (46%) | 11 (61%) | .57 |
| Moderate | 93 (38%) | 6 (33%) | — |
| Severe extended | 40 (16%) | 1 (6%) | — |
| Any graft-versus-host disease (n =262), no. (%) | |||
| Never | 33 (13%) | 4 (22%) | .30 |
| Yes | 211 (94%) | 14 (78%) | — |
— indicates not applicable.